Official Title
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Antipsychotic Drugs in Healthy Humans
Phase
N/ALead Sponsor
Leiden UniversityStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Insulin Resistance DyslipidemiaIntervention/Treatment
haloperidol olanzapine ...Study Participants
11We hypothesized that short-term treatment with AP drugs induces insulin resistance through a mechanistic route that is independent of weight gain and that atypical drugs exert stronger effects than typical compounds in this respect. We therefore treated healthy non-obese men with olanzapine (atypical AP) or haloperidol (typical AP) for 8 days, and studied the impact of these interventions on glucose and lipid metabolism by hyperinsulinemic euglycemic clamp, isotope dilution technology and indirect calorimetry.
olanzapine 10 mg/day for 8 days
haloperidol 3 mg/day for 8 days
Healthy men with a positive family anamneses of schizophrenia
Inclusion Criteria: Healthy men, with and without a positive family history of schizophrenia. 20 kg/m2 < BMI < 26 kg/m2 Age 20-40 years Fasting plasma glucose < 6 mmo/L Exclusion Criteria: FPG > 6 mmol/L BMI > 26 kg/m2 Psychiatric disorders and/or use of antipsychotic or antidepressants drugs at present or in the past. Any significant chronic disease Renal, hepatic or endocrine disease Use of medication known to influence lipolysis and/or glucose metabolism Total cholesterol > 7mmol/L and/or triglycerides > 2 mmol/L Recent weight changes or attempts to loose weight (> 3 kg weight gain or loss, within the last 3 months) Difficulties to insert an intravenous catheter Smoking (current) Severe claustrophobia (ventilated hood) Recent blood donation (within the last 2 months) Recent participation in other research projects (within the last 3 months), participation in 2 or more projects in one year Extensive sporting activities (more than 10 hours of exercise per week)
